Pharmacogenetic Testing
Customize your policy alerts
Sign up for longevityhealthplanofcolorado Policy UM.054 alerts
Get alerted when Policy UM.054 changes without checking for updates manually.
Monitor payer policy activity
Coverage criteria and prior authorization requirements for pharmacogenetic testing for Longevity Health Plan of Colorado members, including which gene–drug pairs (CPIC levels A/B) are considered appropriate. Affects providers ordering pharmacogenetic tests and labs performing them.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medical necessity criteria
Covered when ALL of the following are met:
Clinical records must include an encounter from the ordering provider documenting the diagnosis, history of the condition, the medication therapy attempted or proposed, responses, dates, and a note of any therapeutic failure or medication-related side effects.
Tests assigned CPIC level C or D are not considered to have adequate evidence or clinical actionability and therefore are not appropriate for use under this policy. Longevity Health will only consider pharmacogenetic tests assigned CPIC level A or B to be appropriate for clinical decision-making.
Investigational or experimental pharmacogenetic tests are not considered medically necessary and are excluded from coverage. Longevity Health aligns with CPIC guidance and excludes tests lacking established evidence and prescribing recommendations.
As an example from the gene–drug listing, the entry for PTGS1 – aspirin is annotated with a 'D' classification in the reference table; entries labeled 'D' in the list reflect the plan's categorization distinct from CPIC A/B recommendations and are not considered actionable for coverage under this policy.
Additional examples of gene–drug pairs carrying a 'D' classification in the listing include APOE – atorvastatin, CETP – atorvastatin, COQ2 – atorvastatin, and multiple entries for chemotherapy or cardiology agents (for example, CBR3 and HAS3 with anthracyclines) that are annotated as 'D' in the plan's table.
Requests for pharmacogenetic testing that do not document either a demonstrated therapeutic failure of standard pharmacologic treatment or relevant medication-related side effects in the clinical record may be denied as not medically necessary. Clinical records submitted for authorization must include an encounter from the ordering provider with history, medication therapy attempted and response, and any note of failure or side effects; records must have dates of service within 90 days of the authorization request.
The coverage reference enumerates numerous specific gene–drug associations annotated with a 'D' classification (for example, TYMS – capecitabine, GSTP1 – cisplatin, NQO1 – doxorubicin and many others). These 'D' annotations indicate those pairs are not considered actionable/covered for the purposes of this policy.
Covered Indications
Pharmacogenetic testing for CPIC level A or B gene–drug pairs
Covered indication — testing is appropriate when ALL of the following apply:
Testing must be linked to a specific medication and clinical question; Longevity Health will consider only CPIC level A or B gene–drug pairs appropriate for use.
Covered gene–drug interaction entries (representative examples)
The policy reference lists gene–drug interaction entries used to guide interpretation. Examples include (not exhaustive):
This node lists representative gene–drug pairs drawn from the policy's covered services table; the full policy contains a comprehensive table of entries and CPIC/coverage annotations.
Gene–drug interactions with classification 'C' or 'C/D'
Interpretation note: entries marked 'C' or 'C/D' appear in the covered-services gene–drug table used to guide testing interpretation.
The policy distinguishes CPIC level A/B for coverage appropriateness; separate single-letter coverage classifications (C, D, C/D, etc.) appear alongside listed gene–drug pairs in the reference table.
Provider Actions & Prior Authorization
Prior authorization required for all pharmacogenetic testing
Prior authorization is required for all pharmacogenetic testing. The prior authorization request must be accompanied by clinical records (dates of service within 90 days) that document the member's diagnosis, the targeted medication, prior therapy attempts, and evidence of therapeutic failure or relevant adverse effects.
- Submit clinical encounter from the ordering provider showing diagnosis and the specific drug for which testing is requested.
- Include prior medication therapy attempted, response, and any therapeutic failure or medication-related side effects.
- Ensure supporting clinical records have dates of service within 90 days of the authorization request.
Gene–drug entries do not state prior authorization rules
The gene–drug listing sections enumerate many gene–drug pairs and assign coverage classification codes (e.g., B/C, C, D) but do not specify any additional prior authorization rules within those entries.
- Entries list gene symbols, drugs, and a single-letter coverage/classification code; no per-entry prior authorization instructions are provided in these chunks.
No prior authorization rules or billing codes specified in these entries
The coverage-classified gene–drug tables in these chunks do not include prior authorization procedures or list affected billing codes.
- Content consists of gene–drug pairings and classification codes without billing or authorization guidance.
Demonstrate treatment failure or relevant adverse effects
Medical necessity requires documentation that the member has had therapeutic failure of standard pharmacologic treatment prescribed according to standards of care OR documented medication-related side effects reasonably associated with the medication before testing is considered medically necessary.
- Clinical record must demonstrate prior therapeutic failure of existing/prior pharmacological treatment prescribed in alignment with normal standards of care, or
- Documented side effects reasonably associated with the medication that justify testing.
No step therapy requirements specified
No step therapy requirements are described in these chunks; the document does not impose a formal sequence of therapies beyond the medical necessity demonstration above.
- Ordering requirements focus on documentation of prior treatment response or side effects rather than specified step-therapy pathways.
No explicit provider-action content
No explicit content was extracted for this provider-action callout in the referenced chunks.
Required clinical documentation (records within 90 days)
Clinical records with dates of service within 90 days prior to the authorization request must be provided and include an encounter from the ordering provider documenting the diagnosis, the targeted medication, prior treatment attempted and response, and any therapeutic failure or medication-related side effects.
- Include ordering provider encounter note describing history of condition, medication therapy attempted, dates, and response.
- Attach documentation of therapeutic failure or side effects when relied upon to establish medical necessity.
No documentation requirements in gene–drug listing chunks
These gene–drug pair listing chunks provide only gene, drug, and classification codes and do not specify documentation requirements.
- Do not rely on these listing chunks to determine required supporting clinical documentation.
No explicit provider-action content
No explicit content was extracted for this provider-action callout in the referenced chunks.
Denial risk if test exceeds medical necessity
Tests that exceed the beneficiary's medical need or are not reasonable and necessary under Section 1862(a)(1)(A) may be denied.
- Requests lacking documentation of diagnosis, targeted medication, and either therapeutic failure or relevant side effects (with records within 90 days) may be considered exceeding medical need.
Missing prior authorization may lead to denial
Failure to obtain the required prior authorization for pharmacogenetic testing may result in claim denial, because the policy requires prior authorization for all pharmacogenetic testing.
- Ensure prior authorization is granted before performing pharmacogenetic testing to avoid denial.
No authorization/denial rules in classification entries
The gene–drug coverage classification entries do not contain explicit authorization or denial rules; they present classification codes (B/C, C, D) without authorization guidance.
- Use the policy's coverage criteria and prior authorization sections for authorization requirements rather than relying on the classification table entries.
Classification table lacks authorization/denial rules
The extracted classification-table chunks do not include explicit authorization or denial rules; they focus on gene–drug pair listings and classification codes.
- Refer to the Coverage Criteria and Prior Authorization sections for actionable requirements.
Order must include ordering-provider clinical records and rationale
Order must be accompanied by clinical records from the ordering provider documenting the diagnosis, the targeted medication, prior treatment and response, and rationale (including therapeutic failure or medication-related side effects) supporting medical necessity.
- Provide ordering provider encounter note with history, medication therapy attempted, dates, and response.
- Document rationale linking requested pharmacogenetic test to the specific medication and clinical question.
Coding & Documentation Recency
Not Covered
Pharmacogenetic tests with CPIC level C or D, and tests explicitly considered investigational or experimental, are not covered under this policy. The plan bases coverage determinations on CPIC evidence levels and will only consider tests at CPIC level A or B appropriate for clinical use.
Several gene–drug entries in the plan's listing are assigned the category 'D'; examples shown include PTGS1 – aspirin, APOE – atorvastatin, CETP – atorvastatin, and many other gene–drug pairs annotated as 'D' in the table.
Specific gene–drug pairs documented with the classification 'D' that appear in the extract include, among others, TYMS – capecitabine, GSTP1 – cisplatin, NQO1 – doxorubicin, and multiple additional entries across the chemotherapy and cardiology examples shown; the policy treats these 'D'-labeled pairs as not covered or otherwise excluded from actionability.
Definitions
Background
Pharmacogenetic testing analyzes germline genetic variants that may influence drug metabolism, efficacy, or risk of adverse effects. Longevity Health aligns its coverage with CPIC recommendations and requires that testing be targeted to a specific clinical question tied to a patient's diagnosis and medication regimen; only tests with demonstrated clinical actionability (CPIC level A or B) will be considered for coverage.
Revision History
Policy UM.054 (Pharmacogenetic testing coverage criteria) became effective.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.